Drug Trial Radar · NCT05257083
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
759
Actual
Start
Oct 10, 2023
Primary completion
Jun 2033
Study completion Aug 2040
Sponsor
- Lead sponsor
- Stichting European Myeloma NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- Janssen Research & Development, LLC
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Conditions
- Multiple Myeloma
Interventions
DaratumumabDrug
Daratumumab will be administered SC.
BortezomibDrug
Bortezomib will be administered SC.
LenalidomideDrug
Lenalidomide will be administered orally.
DexamethasoneDrug
Dexamethasone will be administered orally.
Cilta-celDrug
Cilta-cel will be administered intravenously
CyclophosphamideDrug
Cyclophosphamide will be administered intravenously.
FludarabineDrug
Fludarabine will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: up to 10 years ( or 300 PFS events)
- Sustained MRD-negative CRTime frame: up to 24 months
Locations
106 sites in 16 countries. Site status is shown where the registry gives one.
University of Arkansas
Little Rock, Arkansas
City of Hope
Duarte, California
UC San Diego Health Moores Cancer Center
San Diego, California
University of California San Francisco (UCSF)
San Francisco, California
Stanford University
Stanford, California
Moffit Cancer Center
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
University of Chicago
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University Of Maryland Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Center
Detroit, Michigan
Mount Sinai Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
University of Rochester
Rochester, New York
Montefiore M-E Center
The Bronx, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
University of Virginia
Charlottesville, Virginia
University of Washington Medical
Seattle, Washington
Medical College Wisconsin
Milwaukee, Wisconsin
Princess Alexandra Hospital
Brisbane, Australia
Royal Prince Alfred Hospital
Camperdown, Australia
Royal Brisbane and Womens Hospital
Herston, Australia
Alfred Health
Melbourne, Australia
Austin Hospital
Melbourne, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
Westmead Hospital
Westmead, Australia
Jules Bordet Instituut
Anderlecht, Belgium
UZA
Antwerp, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.